Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AMGN with free AI briefings, catalyst countdowns, and dilution alerts.

AMGN · Amgen Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$25.8B Cash on Hand
CF+ Cash Runway
2.3% Short Interest
$432.84 Analyst Target (29)
Follow AMGN by email Get an email when AMGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMGN, unsubscribe in one click. Privacy

📣 What AMGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Evolocumab
FDA approved Aug 2015 · Repatha
Cardiovascular Disease Phase 4 · NCT05284747 Active not recruiting
Erenumab
FDA approved May 2018 · Aimovig
Migraine Phase 3 · NCT03832998 Completed
Romiplostim
FDA approved Aug 2008 · Nplate
Chemotherapy-induced Thrombocytopenia Phase 3 · NCT03362177 Completed
Sotorasib (AMG 510)
FDA approved May 2021 · Lumakras
Non-Small Cell Lung Cancer (NSCLC) Phase 3 · NCT05920356 Recruiting
Tarlatamab
FDA approved May 2024 · Imdelltra
Extensive-Stage Small-Cell Lung Cancer Phase 3 · NCT06211036 Active not recruiting
Tezepelumab
FDA approved Dec 2021 · Tezspire
Eosinophilic Esophagitis Phase 3 · NCT05583227 Active not recruiting
Apremilast
FDA approved Mar 2014 · Otezla
Behçet's Disease Phase 3 · NCT05767047 Recruiting
Carfilzomib
FDA approved Jul 2012 · Kyprolis
Multiple Myeloma Phase 1/2 · NCT04822337 Recruiting
Blinatumomab
FDA approved Dec 2014 · Blincyto
B Precursor Acute Lymphoblastic Leukemia Phase 2 · NCT06054113 Active not recruiting
Routine Lipid Management Cardiovascular Disease Phase 4 · NCT05284747 Active not recruiting
mFOLFOX6 Gastric Cancer Phase 3 · NCT05052801 Completed
Dazodalibep Sjogren's Syndrome Phase 3 · NCT06104124 Completed
Maridebart Cafraglutide Heart Failure With Preserved Ejection Fraction Phase 3 · NCT07037459 Recruiting
ABP 938 8 mg Neovascular Age-related Macular Degeneration Phase 3 · NCT07614776 Recruiting
Olpasiran Atherosclerotic Cardiovascular Disease Phase 3 · NCT05581303 Active not recruiting
Bemarituzumab Gastric Cancer Phase 3 · NCT05052801 Completed

Also used in these trials (approved or third-party drugs, not AMGN's own candidates): Avacopan, Durvalumab, Inebilizumab, Pembrolizumab, Oral Semaglutide, Aflibercept, Mitoxantrone, Ziftomenib, Vorinostat, Pemetrexed Disodium, Methotrexate, Mercaptopurine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMGN holds $25.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMGN files for a raise →

👥 Who Owns AMGN

Insiders 0.2% Institutions (4140 holders) 84.9% Public and other holders 14.9%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 48,925,833 9.05% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 40,510,484 7.49% 2026-03-31
State Street Corporation Institution (13F) 30,955,079 5.72% 2026-09-30
Capital World Investors Institution (13G, 5%+) 29,596,119 5.47% 2026-03-31
Invesco Ltd. Institution (13F) 16,550,564 3.06% 2026-09-30
Geode Capital Management, LLC Institution (13F) 16,041,602 2.97% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 15,053,954 2.78% 2026-09-30
Charles Schwab Investment Management, In Institution (13F) 13,984,272 2.59% 2026-09-30
Morgan Stanley Institution (13F) 13,550,428 2.51% 2026-09-30
Wells Fargo & Company Institution (13F) 6,938,636 1.28% 2026-09-30
Robert A Bradway
Chairman, CEO and President, Director · +79,176 options
Insider 655,220 0.12% 2026-05-07
Esteban Santos
EVP, Operations
Insider 83,757 0.02% 2026-05-07

Share count 540,911,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-06
filed 2026-11-09
HOLLEY CHARLES M
Award (A) 185 – 13,262
2026-11-06
filed 2026-11-09
ISHRAK OMAR
Award (A) 152 – 7,682
2026-11-06
filed 2026-11-09
Gibbs David W
Award (A) 278 – 278
2026-11-06
filed 2026-11-09
Drake Michael V
Award (A) 114 – 6,030
2026-08-13
filed 2026-08-13
Khosla Rachna
Sale (S) 1,252 $416.43 6,404

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AMGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.